Expecting a 15-17% Swing on DTIL as the stock rounds off from it's previous $12.50 Breakout Consolidation. It seems as though profit-taking has completed and the stock is moving higher in the pre-market session to solidify the swing trade. We have been watching the stock for the past few days and the Buying Volume has spiked over the course of that time period. In regards to what could push this stock even higher, the company just announcing receiving positive interim results from it's PBCAR0191 Trial as Potential Lymphoma and Leukemia Treatment. The company also has completed preclinical work for another related drug candidate: PBCAR19B, and expects it to enter the clinical trial in 2021.
Publications connexes
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Publications connexes
Clause de non-responsabilité
Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.